Raffa Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Raffa Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-378	Closed	-$10.1K	–	1159
2024 Q2	$10.1K	Hold	378	–	–	﹤0.01%	438
2024 Q1	$12.9K	Buy	+378	New	+$11.3K	﹤0.01%	384
2017 Q3	–	Sell	-41	Closed	-$1.77K	–	379
2017 Q2	$1.77K	Hold	41	–	–	﹤0.01%	296
2017 Q1	$1.28K	Hold	41	–	–	﹤0.01%	305
2016 Q4	$1.03K	Hold	41	–	–	﹤0.01%	428
2016 Q3	$1.01K	Hold	41	–	–	﹤0.01%	412
2016 Q2	$835	Hold	41	–	–	﹤0.01%	455
2016 Q1	$625	Hold	41	–	–	﹤0.01%	590
2015 Q4	$551	Hold	41	–	–	﹤0.01%	646
2015 Q3	$575	Hold	41	–	–	﹤0.01%	606
2015 Q2	$696	Buy	+41	New	+$584	﹤0.01%	520

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Raffa Wealth Management's SUPN Position: Q3 2024 in Review

Raffa Wealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 378 shares — an estimated $10.1K sold.

Raffa Wealth Management first reported a position in SUPN in Q2 2015 and held it in 11 quarters. The position peaked at $12.9K in Q1 2024. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

Raffa Wealth Management reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Raffa Wealth Management sold 378 Supernus Pharmaceuticals shares in Q3 2024, an estimated $10.1K.
Raffa Wealth Management first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 11 quarters.
Raffa Wealth Management's Supernus Pharmaceuticals position peaked at $12.9K in Q1 2024.
273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on Raffa Wealth Management's 13F filing for Q3 2024, filed 27 Jul 2026.